← back to search

Daphne Chan

Johnson & Johnson (United States) · US
Area of research
Immunology · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Inflammatory Bowel Disease, Spondyloarthritis Studies and Treatments, and Pharmaceutical studies and practices.
h-index
23
citations
2,434
works
92
NIH funding
primary concept
Medicine
email

Recent publications

Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones
JAMA Dermatology 2025cited by 7position: middledoi
Improving Diversity in a Novel Psoriasis Study
JAMA Dermatology 2024cited by 14position: middledoi
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
˜The œLancet. Gastroenterology & hepatology 2023cited by 68position: middledoi
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
British Journal of Dermatology 2023cited by 11position: middledoi
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
Gastroenterology 2022cited by 196position: middledoi
Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
Crohn s & Colitis 360 2020cited by 13position: lastdoi
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease
Gastroenterology 2019cited by 65position: middledoi
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
Gastroenterology 2018cited by 176position: middledoi
Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
The Journal of Clinical Pharmacology 2018cited by 39position: middledoi
Subcutaneous Golimumab in Pediatric Ulcerative Colitis
Inflammatory Bowel Diseases 2017cited by 45position: middledoi
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up
British Journal of Dermatology 2014cited by 203position: middledoi
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
British Journal of Dermatology 2013cited by 409position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Omoniyi J. Adedokun · Johnson & Johnson (United States)5 papers (2017–2022)Mark Lebwohl · Mount Sinai Hospital3 papers (2013–2023)Brian G. Feagan · Western University3 papers (2018–2022)Dan Turner · Oxford Nanopore Technologies (United Kingdom)3 papers (2017–2020) · 3 papers (2013–2018)Richard Strauß · Janssen (United States)3 papers (2017–2020)Jeffrey S. Hyams · S.P.E.C.I.E.S.3 papers (2017–2020)William J. Sandborn · Mirati Therapeutics (United States)3 papers (2018–2022) · 2 papers (2017–2020)Joel R. Rosh · North Shore Diabetes and Endocrine Associates2 papers (2017–2020) · 2 papers (2017–2020)Anne M. Griffiths · SickKids Foundation2 papers (2017–2020) · 2 papers (2014–2023)Paul Rutgeerts · KU Leuven2 papers (2018–2019)Ghassan Wahbeh · Seattle Children's Hospital2 papers (2017–2020)Paul Pollack · AbbVie (United States)2 papers (2018–2019) · 2 papers (2013–2014)Kristian Reich · Universität Hamburg2 papers (2013–2014)Melvin B. Heyman · University of California, San Francisco2 papers (2017–2020)Kim Papp · Goethe University Frankfurt2 papers (2013–2023)